Background Approximately 800,000 children die each year due to pneumococcal disease and> 90% of these deaths occur in developing countries where few children have access to …
A Gentile, A Bardach, A Ciapponi, S Garcia-Marti… - International Journal of …, 2012 - Elsevier
BACKGROUND: This systematic review evaluated the incidence, etiology, and use of resources in bacterial, non-tuberculosis community-acquired pneumonia (CAP) in immune …
E Theodoratou, S Johnson, A Jhass… - International journal …, 2010 - academic.oup.com
Background With the aim of populating the Lives Saved Tool (LiST) with parameters of effectiveness of existing interventions, we conducted a systematic review of the literature …
MT Valenzuela, R O'Loughlin… - … de Salud Pública, 2009 - SciELO Public Health
OBJECTIVE: To conduct a comprehensive review of data on pneumococcal disease incidence in Latin America and the Caribbean and project the annual number of …
V Suarez, F Michel, CM Toscano, AL Bierrenbach… - Vaccine, 2016 - Elsevier
Streptococcus pneumoniae is the leading cause of bacterial pneumonia, meningitis and sepsis in children worldwide. Despite available evidence on pneumococcal conjugate …
A Bardach, A Ciapponi, S Garcia-Marti… - International journal of …, 2011 - Elsevier
BACKGROUND: Acute otitis media (AOM) is one of the most common childhood diseases requiring antimicrobial prescription in pre-school children. This systematic review aimed to …
P Gagetti, SW Lo, PA Hawkins… - Microbial …, 2021 - microbiologyresearch.org
Invasive disease caused by Streptococcus pneumoniae (IPD) is one of the leading causes of morbidity and mortality in young children worldwide. In Argentina, PCV13 was introduced …
A Sinha, D Constenla, JE Valencia… - … de Salud Pública, 2008 - SciELO Public Health
OBJECTIVE: In Latin America and the Caribbean, routine vaccination of infants against Streptococcus pneumoniae would need substantial investment by governments and donor …
BACKGROUND: Currently there are three pneumococcal conjugate vaccines with different coverage of serotypes for use in children under one year. We evaluate the cost-effectiveness …